Wellbeing Checkup: Cutting-Edge Science Improves Patient Outcomes

Burnout seemed to be at an all-time high for health care providers during the COVID-19 pandemic. When it comes to treating patients with blood cancer, their immunocompromised status put even more stress on doctors, as they now had an added layer of worry and concern for the people they were treating. However, when major advances enter the space – such as the recent FDA approval of cilta-cel for pretreated, relapsed/refractory multiple myeloma – clinicians can once again feel empowered and exciting, explained Dr. Sundar Jagannath, MBBS, professor of Medicine and director of the Multiple Myeloma Center of Excellence at the Tisch Cancer Institute in New York.